Latest news with #LifeScience
Wall Street Journal
24-04-2025
- Health
- Wall Street Journal
Finley Approaches a Slippery Slope on SNAP
Allysia Finley is on a slippery slope when she argues that Supplemental Nutrition Assistance Program, or SNAP, beneficiaries ought not be allowed to purchase candy or sodas with their food stamps ('Do Food Stamps Make People Fat?,' Life Science, April 21). True enough: Such consumption except in moderation isn't healthy. Why should the taxpayers subsidize it? Also true: The federal government spends almost $2 trillion annually—over a quarter of all federal outlays—on healthcare. Under Ms. Finley's principle it would be appropriate for the government to withhold such benefits for given people unless they adhere to government diktats on such lifestyle choices as individual diets, exercise habits and so forth. More monitoring of Americans in their daily lives would be guaranteed. Thus are we confronted with the age-old conservative principle: More government inexorably yields less freedom. Ronald Reagan was right yet again when he observed that 'the nine most terrifying words in the English language are 'I'm from the government, and I'm here to help.' '
Zawya
10-04-2025
- Business
- Zawya
UiPath announces AI partnership with Google Cloud to transform medical processes
Dubai, United Arab Emirates – UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced the launch of its generative AI-based UiPath Medical Record Summarization agent, powered by Google Cloud Vertex AI and Gemini models. The UiPath Medical Record Summarization AI agent, now in private preview for customers, empowers both payer and provider organizations to take complete advantage of the combined power of gen AI and agentic automation. Developed in partnership with top clinical professionals, the solution leverages Google Gemini 2.0 Flash through Vertex AI to create a more efficient and accurate way to analyze medical documents. The agent is part of UiPath's strategy to provide vertical AI solutions tailored to specific industry needs. Built with UiPath Agent Builder, the agent provides a clinician-level, multi-point summarization of voluminous records at lower cost and with higher quality and accuracy than manual data entry, completing in just minutes a process that typically takes a medical professional an average of 45 minutes. This improves overall efficiency for healthcare organizations through: Reducing the time and effort required for manual summarization thereby increasing cost savings, lessening the need for rework, and improving revenue opportunities Significantly decreasing time spent on tasks such as patient referral intake, order intake, and utilization management reviews, saving up to 40 minutes per referral and reducing overall prior authorization turn-around time by up to 50% Ensuring medical summaries are consistent and high quality with standardized sections and traceable data, improving the accuracy of clinical decisions and reducing errors Providing a structured and organized summary of medical records, enabling clinicians and coordinators to make informed decisions more quickly and confidently 'Chief Medical Officers, Chief Financial Officers, and CIOs at healthcare organizations are consistently under pressure to reduce costs and improve quality of care while dealing with people resource constraints. Currently, clinical and non-clinical staff must summarize large volumes of medical records, yet medical records lack standard formats and summaries meaning they vary in quality and standardization,' said Mark Geene, senior vice president of AI Products at UiPath. 'By automating and streamlining summary creation with Google Cloud, UiPath enables healthcare organizations to save clinical review time and improve accuracy, generating significant annual value in time savings and cost avoidance.' 'UiPath is delivering on its strategy to provide vertical AI solutions that are built to address industry-specific needs,' said Shweta Maniar, global director for Healthcare & Life Science Strategy & Solutions at Google Cloud. 'Powered by Vertex AI and Gemini models, UiPath's new medical summarization agent will significantly improve efficiency and streamline business processes for healthcare organizations.' The new solution benefits both payer and provider organizations by providing quick access to accurate information from medical records and streamlining critical processes such as utilization management, appeals, referrals and order intake, and clinical trial eligibility checks. The UiPath Medical Record Summarization agent is already deployed by a major healthcare payer, which is using the agent to improve speed and accuracy of document processing to achieve results 23% faster. UiPath Medical Records Summarization delivers: Clinician-level summaries organized in easy-to-understand segments with traceable citations. Records are displayed in an organized format, enabling quick location and review of relevant information State-of-the-art retrieval-augmented generation (RAG) for processing unstructured medical record data, projected to deliver faster chart processing from intake to summary Reduction of administrative tasks for both clinical and non-clinical professionals UiPath partnership with Google Cloud Vertex AI makes it easy to build, deploy, and manage ML models and generate fast, cost-effective predictions. UiPath customers can now harness the power of the latest ML models through Vertex AI to build into business processes quickly and seamlessly without the need for complex coding and manual effort. UiPath is available on Google Cloud Marketplace to enable Google Cloud customers to purchase the industry-leading UiPath Platform and reliably deploy and scale their automation initiatives on Google Cloud infrastructure. Today, customers can deploy UiPath Studio and UiPath automations on Google Cloud in minutes. UiPath also recently expanded its partnership with Google Cloud to help customers facilitate their AI-powered automation journey through Google Workspace business collaboration offerings. Visit here to learn more about innovating with UiPath and Google Cloud. About UiPath UiPath (NYSE: PATH) develops AI technology that mirrors human intelligence with ever-increasing sophistication, transforming how businesses operate, innovate, and compete. The UiPath Platform™ accelerates the shift toward a new era of agentic automation—one where agents, robots, people, and models integrate seamlessly to enable autonomous processes and smarter decision making. With a focus on security, accuracy, and resiliency, UiPath is committed to shaping a world where AI enhances human potential and revolutionizes industries. For more information, visit For more information, please contact: uipath@
Yahoo
17-03-2025
- Business
- Yahoo
Celex Oncology Announce Novel Mechanism in Cancer Care and Attendance at Bio-Europe Spring 2025
LONDON, March 17, 2025 (GLOBE NEWSWIRE) -- Celex Oncology, a UK biotechnology company founded in 2017 and on the brink of launching the fourth revolution in cancer care, today announced the Celex model and investigative treatment. The treatment* has the potential to control metastatic cancer and block the processes that lead to advanced metastatic disease, which is responsible for approximately 90% of all cancer deaths globally.1 Despite advances in oncology, the aggressive nature of many cancers continues to pose significant challenges, with unresolved disease progression, treatment-induced side-effects and resistance to treatment remaining key issues.2 To date, three major paradigms have existed in cancer care with Celex Oncology proposing a new paradigm: targeting sodium overload in tumour cells*. Several recent research papers stress the importance of the understanding of the bioelectricity of cancer for treatments3 and the involvement of voltage-gated sodium channels (VGSCs) in progression and metastasis.4 This research underscores its significance as a potential novel therapeutic target. Celex Oncology is investigating VGSC inhibitors which have the potential to reverse cancer progression and harness the power of bioelectricity, reversing and blocking the processes that lead to advanced and deadly oncological disease. Celex Oncology is in attendance at the Bio-Europe Spring 2025 scientific congress (17th – 19th March) in Milan, Italy, where leadership will be meeting with investors, pharma & biotech companies and industry experts to discuss their technology and investigational plan. Celex Oncology's first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult programme, which recognises and awards the highest-potential life science and health tech start-ups. Celex Oncology took home the Life Science award in their potential treatment for invasive and metastatic cancer.5 'At Celex Oncology, we are steadfast in our determination to deliver an alternative option for patients with metastatic cancer. We have spent years deepening our understanding of cancer invasion and progression. In addition to our VGSC inhibitors we are developing tumour specific monoclonal antibodies (mAb) to target a key protein present in invasive breast and colon cancer. This has been undertaken by identifying a special version of a tissue protein that appears in tumours and aids in metastasis,' said Dr Sara Moodad, Vice President of Research & Development, Celex Oncology. 'We are advancing rapidly towards clinical trials, aiming to significantly improve both survival and quality of life, with a therapeutic option complementary to existing treatments.' Carsten Faltum, CEO, Celex Oncology, said, 'We're delighted to be at Bio-Europe Spring 2025 alongside other life science and biotech leaders. We are here to continue our journey of bringing new solutions to long-term and unresolved issues in cancer care. Our investigational treatments are designed to control tumours and thereby improve survival. They have the potential to be transformative and could change metastatic cancer care by turning it from a life-threatening disease into a controlled and treatable long-term condition. We are looking forward to discussions about Celex Oncology and our goals, which will empower clinicians and could lead to a future where cancer is no longer synonymous with inevitable decline but instead a controllable condition that allows a person living with cancer to lead a longer, more active, more productive life.' While VGSC inhibitors will need to undergo further testing to realise their clinical potential, the possibility of managing metastatic cancer in a non-toxic and cost-effective way is promising and 'should be welcomed by cancer patients and clinicians'.4 Notes for Editors Fact Box Celex Oncology is harnessing the power of bioelectricity, targeting voltage-gated sodium channels (VGSCs) to reverse cancer cell aggression and block the processes that lead to advanced oncological disease The drug will be a daily, oral pill that restores normal intracellular sodium level. Sodium is one of the most crucial and fundamental cell components with a key role in regulation of many vital cell processes and tumour cell behaviour. This novel mechanism of action and new target is supported by robust preclinical data and real-world evidence (RWE) in several indications demonstrating a significant pan-cancer opportunity. Founded in 2017, Celex Oncology is transforming cancer care by turning it from a life-threatening disease into a controlled and treatable long-term condition. The first-in-class, proprietary treatment will target sodium overload in tumour cells – one of the most crucial cell components and key regulators of tumour cell behaviour. Sodium is one of the most crucial and fundamental cell components with a key role in regulation of many vital cell processes and tumour cell behaviour. Celex Oncology's CL-S01 and CL-S03 treatments*, still in investigational stage, aim to improve both survival and quality of life. Designed for rapid integration into existing clinical regiments, the cost-effective and easy-to-administer approach could redefine the future of cancer care. The strong business model is centred around four separate but inter-linked areas within the product profile: tumour treatment, monoclonal antibodies, diagnostic and cardiac protection. Follow Celex Oncology's journey on LinkedIn Contact Details Stephanie Harris, Associate Director, MD Health +44 (0)7590562038 References Hudock, N.L. et al. (2023) 'Future trends in incidence and long-term survival of metastatic cancer in the United States', Communications Medicine, 3(1), pp. 1–7. Available at: Mayo Clinic Staff (2022) Managing the lingering side effects of cancer treatment, Mayo Clinic. Available at: Last accessed March 2025. Pukkanasut, P. et al. (2024) 'Therapeutic targeting of voltage-gated sodium channel NaV1.7 for cancer metastasis', Frontiers in Pharmacology, 15. Available at: Djamgoz, M.B.A. (2024) 'Electrical excitability of cancer cells—CELEX model updated', Cancer and Metastasis Reviews, 43(4), pp. 1579–1591. Available at: Europe's next generation of elite health innovation start-ups recognised - EIT Health (2024) EIT Health. Available at: Last accessed March 2025. * Investigational treatment only, not approved for use A photo accompanying this announcement is available at
Reuters
18-02-2025
- Business
- Reuters
Merck KGaA to replace two executives with company veterans
FRANKFURT, Feb 18 (Reuters) - Germany's Merck KGaA ( opens new tab said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but it added that its strategy remains unchanged. Jean-Charles Wirth is to become the CEO of the Life Science unit, a maker of gear and supplies for biotech labs, succeeding Matthias Heinzel, who has decided to not renew his contract. Wirth currently heads the Science & Lab Solutions subunit within Life Science, the company said in a statement. Danny Bar-Zohar, currently the head of drug research and development, will become CEO of the pharmaceuticals division, succeeding Peter Guenter, who has decided to retire from Merck, it added. In addition, Khadija Ben Hammada will assume the newly created role of Chief People Officer on March 1, as Merck adds a sixth executive board seat. She currently holds the title of Chief Human Resources Officer and will take on additional responsibilities in areas such as sustainability, compliance and site management of the headquarters in Darmstadt. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Wall Street Journal
11-02-2025
- Politics
- Wall Street Journal
Republican States Are ‘Wards of Washington'
In her column 'Democratic States Are Wards of Washington' (Life Science, Feb. 3), Allysia Finley writes of certain states' dependence on undisciplined federal 'handouts.' Yet her analysis misses half of the equation: Expenses make sense only when matched with revenues. Public research has repeatedly shown blue-state tax dollars contributed to the federal government subsidize red state receipts from the federal government. Six of the top 10 states receiving the greatest dollar amount of federal grants per capita are red states.
